Artiva Biotherapeutics, Inc. (ARTV) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 4 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for ARTV is $20.50, representing a +125.3% upside from the current price of $9.1. Price targets range from a low of $18.00 to a high of $23.00.
